$IMMX SEC Filings

Filed On	Filing
27 Oct 2026	SCHEDULE 13G
30 Sep 2026	8-K: Other Events Immix Biopharma, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule I
29 Sep 2026	FWP
29 Sep 2026	424B5
29 Sep 2026	8-K: Regulation FD Disclosure; Other Events Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Rel...
14 Aug 2026	SCHEDULE 13G
13 Aug 2026	SCHEDULE 13G/A
07 Aug 2026	10-Q
20 Jul 2026	8-K: Other Events
05 Jun 2026	SCHEDULE 13G/A
29 May 2026	Form 4: Adams Helen C., Director Received 6,250 shares as a grant or award · Granted 12,500 Stock Option (Right to Buy)
29 May 2026	Form 4: Ng Carey, Director Received 6,250 shares as a grant or award · Granted 12,500 Stock Option (Right to Buy)
29 May 2026	Form 4: Marquet Magda, Director Received 6,250 shares as a grant or award · Granted 12,500 Stock Option (Right to Buy)
29 May 2026	Form 4: Morris Gabriel S, Director Granted 500,000 Stock Option (Right to Buy)
29 May 2026	Form 4: Chang Nancy T, Director Received 6,250 shares as a grant or award · Granted 12,500 Stock Option (Right to Buy)
29 May 2026	Form 4: Rachman Ilya M, Director Granted 500,000 Stock Option (Right to Buy)
29 May 2026	Form 4: Chudnovsky Yekaterina, Director Received 6,250 shares as a grant or award · Granted 12,500 Stock Option (Right to Buy)
29 May 2026	Form 4: Hsu Jason, Director Received 6,250 shares as a grant or award · Granted 12,500 Stock Option (Right to Buy)
29 May 2026	Form 4: Buchan Jane, Director Received 6,250 shares as a grant or award · Granted 12,500 Stock Option (Right to Buy)
29 May 2026	8-K: Submission of Matters to a Vote of Security Holders

Comments